RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients (Q36414524)

14 August 2017

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients (English)

1 reference

14 August 2017

1 reference

1 reference

18

Eithan Galun

0 references

author name string

Talia Golan

1

1 reference

14 August 2017

Elina Zorde Khvalevsky

2

1 reference

14 August 2017

Ayala Hubert

3

1 reference

14 August 2017

Rachel Malka Gabai

4

1 reference

14 August 2017

Naama Hen

5

1 reference

14 August 2017

Amiel Segal

6

1 reference

14 August 2017

Abraham Domb

7

1 reference

14 August 2017

Gil Harari

8

1 reference

14 August 2017

Eliel Ben David

9

1 reference

14 August 2017

Stephen Raskin

10

1 reference

14 August 2017

Yuri Goldes

11

1 reference

14 August 2017

Eran Goldin

12

1 reference

14 August 2017

Rami Eliakim

13

1 reference

14 August 2017

Maor Lahav

14

1 reference

14 August 2017

Yael Kopleman

15

1 reference

14 August 2017

Alain Dancour

16

1 reference

14 August 2017

Amotz Shemi

17

1 reference

14 August 2017

language of work or name

English

0 references

publication date

19 May 2015

1 reference

14 August 2017

1 reference

14 August 2017

6

1 reference

14 August 2017

27

1 reference

14 August 2017

24560-24570

1 reference

Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas

14 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

RNAi therapies: drugging the undruggable

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Mutant KRAS is a druggable target for pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Genetic and epigenetic alterations in pancreatic carcinogenesis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Molecular genetics of pancreatic intraepithelial neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Diagnostic utility of K-ras mutations in fine-needle aspirates of pancreatic masses.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4695206

Molecular biology of pancreatic cancer

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26009994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Kinetics of interaction of nucleotides with nucleotide-free H-ras p21

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26009994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.4183

0 references

1 reference

14 August 2017

PubMed publication ID

26009994

1 reference